Ifactor biologic full#

I-FACTOR+ MATRIX utilizes a small proprietary peptide (P-15) technology developed by Cerapedics to support bone growth through cell attraction, attachment, and activation. ' Canada will be the first market offering the i-FACTOR+ MATRIX product, which leverages the clinically proven P-15 osteogenic cell-binding peptide combined with a collagen carrier for optimized handling.' 'We are excited to announce that i-FACTOR+ Matrix is now fully available in Canada through our distributor Surgi-One and can be used in both spine and general orthopedic applications,' said Glen Kashuba, Chief Executive Officer of Cerapedics.

Ifactor biologic full#

5, 2020 /CNW/ - Cerapedics, a private ortho-biologics company, today announced the full commercial availability of i-FACTOR+ MATRIX for surgical implantation in Canada. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.Ĭontact us to discuss partnering with Legacy MedSearch on your position.Canada will be the first commercial market to launch i-FACTOR ®+ Matrix We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research &, quality & regulatory, project management, field service, and clinical affairs. Our clients include both blue-chip companies and innovative startups within the MedTech space. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. See Full Press Release at the Source: Cerapedics Announces Canadian Approval of its next-generation bone graft | Cerapedics i-FACTOR Peptide Enhanced Bone Graft must be used inside an allograft bone ring and with supplemental anterior plate fixation.

In the United States, i-FACTOR Peptide Enhanced Bone Graft is indicated for use in skeletally mature patients for reconstruction of a degenerated cervical disc at one level from C3-C4 to C6-C7 following single-level discectomy for intractable radiculopathy (arm pain and/or a neurological deficit), with or without neck pain, or myelopathy due to a single-level abnormality localized to the disc space, and corresponding to at least one of the following conditions confirmed by radiographic imaging (CT, MRI, X-rays): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes), and/or visible loss of disc height as compared to adjacent levels, after failure of at least 6 weeks of conservative treatment. In 2018, the company enrolled the first patients in an IDE clinical trial, ASPIRE, evaluating the safety and efficacy of its next-generation product, P-15L Peptide Enhanced Bone Graft, for use in patients undergoing TLIF fusion surgery. Food and Drug Administration (FDA) premarket approval (PMA) application in 2015 only for use in single-level anterior cervical fusion procedures. In the United States, i-FACTOR Peptide Enhanced Bone Graft was approved via a U.S. i-FACTOR Peptide Enhanced Bone Graft was approved in the European Union in 2008 and Australia in 2010 for use in the repair of bony voids or defects in orthopedic applications throughout the skeletal system (i.e., the spine and extremities). In spinal fusion procedures, surgeons use a bone graft to join and stabilize vertebrae. I-FACTOR Peptide Enhanced Bone Graft is based on proprietary small peptide (P-15) technology developed by Cerapedics to support bone growth through cell attraction, attachment, and activation. i-FACTOR+ Matrix is the same technology as the P15-L investigational material in the IDE.,” said Jeffrey Marx, Ph.D., President and Chief Operating Officer of Cerapedics. “In addition to an anticipated commercial launch in Canada this October, the technology is currently being studied in our FDA IDE study, ASPIRE, targeting lumbar fusions (TLIF), as previously announced.

“We are excited to announce Canadian regulatory approval of our next-generation product, based on P15 osteogenic cell-binding peptide, i-FACTOR+ Matrix,” said Glen Kashuba, Chief Executive Officer of Cerapedics, “The matrix product leverages the clinically proven power of the P15 peptide combined with a collagen carrier for optimized interoperative delivery.” Cerapedics, a private ortho-biologics company, today announced the Health Canada approval of the company’s next-generation bone graft called i-FACTOR+ Matrix, making it the first market to approve the commercial launch of this product.